Strategies for optimizing combinations of molecularly targeted anticancer agents.

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov (2009) 3.20

Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther (2013) 2.64

Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol (2010) 2.36

Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc Natl Acad Sci U S A (2008) 2.22

Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Syst Biol (2011) 1.98

Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep (2009) 1.97

Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res (2008) 1.96

The emerging role of splicing factors in cancer. EMBO Rep (2008) 1.83

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov (2010) 1.59

Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer (2013) 1.39

Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25

High-order combination effects and biological robustness. Mol Syst Biol (2008) 1.24

Nanoconjugate based on polymalic acid for tumor targeting. Chem Biol Interact (2007) 1.22

Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer (2012) 1.19

Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev (2013) 1.11

Drosophila cancer models. Dev Dyn (2011) 1.10

Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther (2009) 1.10

Improved network performance via antagonism: From synthetic rescues to multi-drug combinations. Bioessays (2010) 1.07

Targeting cancer with kinase inhibitors. J Clin Invest (2015) 1.05

Adaptive designs for dual-agent phase I dose-escalation studies. Nat Rev Clin Oncol (2013) 1.04

Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res (2014) 1.01

Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways. PLoS Comput Biol (2013) 1.00

Molecular networks in drug discovery. Crit Rev Biomed Eng (2010) 0.98

Hedgehog signaling in prostate cancer and its therapeutic implication. Int J Mol Sci (2013) 0.96

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. Invest New Drugs (2009) 0.93

Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol (2009) 0.93

Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem (2011) 0.93

Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol Cancer Ther (2012) 0.92

Miniaturized pre-clinical cancer models as research and diagnostic tools. Adv Drug Deliv Rev (2013) 0.89

Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer. Mol Ther (2014) 0.89

Chemogenomics and orthology-based design of antibiotic combination therapies. Mol Syst Biol (2016) 0.85

Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells. Mol Carcinog (2012) 0.85

Prediction of multidimensional drug dose responses based on measurements of drug pairs. Proc Natl Acad Sci U S A (2016) 0.84

Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene (2015) 0.84

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis (2015) 0.84

TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms. Mol Oncol (2013) 0.84

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future. Front Oncol (2014) 0.82

Cancer immunotherapy turns viral. Oncoimmunology (2013) 0.82

Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models. Mol Clin Oncol (2014) 0.82

Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol (2013) 0.81

Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity. Cancer Lett (2014) 0.81

Automated Quantitative Analysis of p53, Cyclin D1, Ki67 and pERK Expression in Breast Carcinoma Does Not Differ from Expert Pathologist Scoring and Correlates with Clinico-Pathological Characteristics. Cancers (Basel) (2012) 0.80

Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. Oncoimmunology (2012) 0.80

Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways. PLoS One (2013) 0.80

The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol (2015) 0.79

Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med (2008) 0.79

An effective solution to discover synergistic drugs for anti-cerebral ischemia from traditional Chinese medicinal formulae. PLoS One (2013) 0.79

Optimizing combinations of flavonoids deriving from astragali radix in activating the regulatory element of erythropoietin by a feedback system control scheme. Evid Based Complement Alternat Med (2013) 0.79

Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer. Mol Oncol (2014) 0.79

Impact of fixed-dose combination of germacrone, curdione, and furanodiene on breast cancer cell proliferation. Cell J (2013) 0.79

Cancer classification: Mutual information, target network and strategies of therapy. J Clin Bioinforma (2012) 0.79

What does it take to synergistically combine sub-potent natural products into drug-level potent combinations? PLoS One (2012) 0.79

The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. Cancer Med (2016) 0.78

Combined drug action of 2-phenylimidazo[2,1-b]benzothiazole derivatives on cancer cells according to their oncogenic molecular signatures. PLoS One (2012) 0.78

Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel) (2015) 0.78

Combination of ruthenium(II)-arene complex [Ru(η(6)-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. Sci Rep (2017) 0.77

Approaches to modernize the combination drug development paradigm. Genome Med (2016) 0.77

Tumor burden talks in cancer treatment with PEGylated liposomal drugs. PLoS One (2013) 0.77

EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins. J Neurooncol (2009) 0.77

Nano-polypharmacy to treat tumors: coencapsulation of drug combinations using nanoparticle technology. Mol Ther (2014) 0.77

KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatments. Per Med (2013) 0.77

Novel beta-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapy. J Drug Target (2010) 0.77

Correlation between radioactivity and chemotherapeutics of the (111)In-VNB-liposome in pharmacokinetics and biodistribution in rats. Int J Nanomedicine (2012) 0.76

Development of a chimeric c-Src kinase and HDAC inhibitor. ACS Med Chem Lett (2013) 0.76

Advances in drug delivery system for platinum agents based combination therapy. Cancer Biol Med (2015) 0.75

Intravenous infusion of phage-displayed antibody library in human cancer patients: enrichment and cancer-specificity of tumor-homing phage-antibodies. Cancer Immunol Immunother (2013) 0.75

Pharmacokinetics and dosimetry of (111)In/(188)Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models. Cancer Biother Radiopharm (2011) 0.75

Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway. Sci Rep (2017) 0.75

Combination therapeutics in complex diseases. J Cell Mol Med (2016) 0.75

A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Hum Vaccin Immunother (2015) 0.75

Akt2 and acid ceramidase cooperate to induce cell invasion and resistance to apoptosis. Cell Cycle (2013) 0.75

Modeling Tumor Clonal Evolution for Drug Combinations Design. Trends Cancer (2016) 0.75

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models. Transl Oncol (2017) 0.75

Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration. Stat Med (2016) 0.75

Synthesis and biological evaluation of novel platinum complexes of imidazolyl-containing bisphosphonates as potential anticancer agents. J Biol Inorg Chem (2015) 0.75

Update on molecular-targeted therapy in hematologic malignancies. Int J Clin Oncol (2007) 0.75

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol (2007) 3.85

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53

Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2008) 2.06

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol (2013) 1.99

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 1.83

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov (2010) 1.59

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol (2007) 1.49

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res (2011) 1.48

Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol (2011) 1.45

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol (2012) 1.37

Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest (2004) 1.33

Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res (2006) 1.33

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol (2008) 1.23

Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol (2010) 1.23

A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res (2009) 1.19

Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer (2013) 1.01

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat (2013) 0.99

Immune checkpoint inhibitors in clinical trials. Chin J Cancer (2014) 0.98

A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother (2011) 0.93

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol (2010) 0.90

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs (2013) 0.88

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol (2011) 0.86

A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs (2014) 0.84

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J (2012) 0.83

A pilot study of bevacizumab and interferon-α2b in ocular melanoma. Am J Clin Oncol (2011) 0.79

Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist (2014) 0.78

Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clin Colorectal Cancer (2010) 0.77

Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting. Chin J Cancer (2014) 0.76

Cancer immunotherapy. Chin J Cancer (2014) 0.75

Foreword. Curr Probl Cancer (2010) 0.75